New concepts for CML clonality

Oncotarget

Volumn 4, Issue 1, 2013, Pages 7-8

  Khorashad, Jamshid S ^a   Deininger, Michael W ^a   O'Hare, Thomas ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL 1 PROTEIN; BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB; PONATINIB; UNCLASSIFIED DRUG;

CANCER CELL; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; DNA REPAIR; DRUG INDICATION; EDITORIAL; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; MISSENSE MUTATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; POINT MUTATION; PROTEIN FUNCTION;

EID: 84875765352     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.882     Document Type: Editorial

References (9)

1. Cortes JE, Kantarjian H, Shah N, et al. N Engl J Med. 2012; 367:2075-2088.
2. Cramer K, Nieborowska-Skorska M, Koptyra M, et al. Cancer Res. 2008; 68:6884-6888.
3. Fernandes MS, Reddy MM, Gonneville JR, et al. Blood. 2009; 114:1813-1819.
4. Khorashad JS, Kelley TW, Szankasi P, et al. Blood. 2013; 121:489-498.
5. Khorashad JS, Milojkovic D, Mehta P, et al. Blood. 2008; 111:2378-2381.
6. Martincorena I, Seshasayee AS and Luscombe NM. Nature. 2012; 485:95-98.
7. O'Hare T, Shakespeare WC, Zhu X, et al. Cancer Cell. 2009; 16:401-412.
8. Shah NP, Skaggs BJ, Branford S, et al. J Clin Invest. 2007; 117:2562-2569.
9. Soverini S, Gnani A, Colarossi S, et al. Blood. 2009; 114:2168-2171.